Based on WHO classification guidelines, we did not designate this case as an MPN associated with PDGFRβ rearrangement due to the lack of a fusion gene and we did not anticipate a favorable response to imatinib-related therapy. The gene discussed is PDGFRB; the disease is myeloproliferative disorder.